JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

Search

MannKind Corp

Gesloten

SectorGezondheidszorg

3.51 2.93

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.51

Max

3.54

Belangrijke statistieken

By Trading Economics

Inkomsten

5.7M

13M

Verkoop

1.6M

78M

K/W

Sectorgemiddelde

39.2

34.393

Winstmarge

16.793

Werknemers

403

EBITDA

8.3M

27M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+163.92% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-316M

1.2B

Vorige openingsprijs

0.58

Vorige sluitingsprijs

3.51

Nieuwssentiment

By Acuity

14%

86%

21 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

MannKind Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 aug 2025, 21:43 UTC

Winsten

Constellation Software 2Q Revenue Rises, Profit Shrinks

8 aug 2025, 16:39 UTC

Acquisities, Fusies, Overnames

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8 aug 2025, 22:42 UTC

Acquisities, Fusies, Overnames

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8 aug 2025, 21:31 UTC

Marktinformatie
Winsten

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8 aug 2025, 21:00 UTC

Winsten

Constellation Software 2Q Rev $2.84B >CSU.T

8 aug 2025, 21:00 UTC

Winsten

Constellation Software 2Q Net $56M >CSU.T

8 aug 2025, 21:00 UTC

Winsten

Constellation Software 2Q EPS $2.66 >CSU.T

8 aug 2025, 20:55 UTC

Marktinformatie

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8 aug 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

8 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 aug 2025, 20:35 UTC

Marktinformatie

Mexico's Industrial Production Seen Higher in June -- Market Talk

8 aug 2025, 20:28 UTC

Winsten

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8 aug 2025, 20:28 UTC

Winsten

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 aug 2025, 20:20 UTC

Acquisities, Fusies, Overnames

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8 aug 2025, 20:08 UTC

Winsten

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8 aug 2025, 19:34 UTC

Marktinformatie

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 aug 2025, 19:15 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8 aug 2025, 19:13 UTC

Marktinformatie

Oil Futures End Volatile Week Lower -- Market Talk

8 aug 2025, 18:21 UTC

Marktinformatie

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8 aug 2025, 17:27 UTC

Winsten

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 aug 2025, 17:09 UTC

Winsten

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 aug 2025, 17:03 UTC

Winsten

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 aug 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

8 aug 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 aug 2025, 15:53 UTC

Acquisities, Fusies, Overnames

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8 aug 2025, 15:51 UTC

Acquisities, Fusies, Overnames

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8 aug 2025, 15:50 UTC

Acquisities, Fusies, Overnames

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8 aug 2025, 15:48 UTC

Acquisities, Fusies, Overnames

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8 aug 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8 aug 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Peer Vergelijking

Prijswijziging

MannKind Corp Prognose

Koersdoel

By TipRanks

163.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.29 USD  163.92%

Hoogste 12 USD

Laagste 7 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor MannKind Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

4.079 / 4.323Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

21 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.